J&J's CAPLYTA (lumateperone) Meets Primary Endpoint in Pivotal Phase 3 Bipolar I Mania Study
核心洞察
Once-daily CAPLYTA 42 mg produced a statistically significant 4.8-point greater reduction in YMRS total score versus placebo at Week 3 in adults with bipolar I mania.
Significant separation from placebo was observed as early as Day 3 and sustained through Week 3, with 45.8% of treated patients achieving clinical response versus 20.9% on placebo.
The key secondary endpoint of Clinical Global Impression-Severity also favored lumateperone, and the safety profile was consistent with the drug's established tolerability.
Johnson & Johnson reported positive topline results from its pivotal Phase 3 Study 451 evaluating CAPLYTA (lumateperone) for the treatment of manic episodes, with or without mixed features, in adults with bipolar I disorder (搜索). The study met its primary endpoint, with the oral atypical antipsychotic demonstrating a statistically significant and rapid reduction in manic symptoms versus placebo at Week 3, and significant improvement observed as early as Day 3. The findings were presented in a late-breaking presentation at the 2026 Psych Congress Annual Meeting in New Orleans, among 24 Johnson & Johnson neuropsychiatry presentations at the meeting.
CAPLYTA is not currently approved for the treatment of manic episodes associated with bipolar I disorder (搜索).
Trial Design and Efficacy Results
Study 451 was a randomized, double-blind, placebo-controlled trial that evaluated once-daily CAPLYTA 42 mg versus placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I disorder (搜索) (NCT06462586). It is the first of two pivotal Phase 3 studies of lumateperone in this indication.
On the primary endpoint, CAPLYTA produced a 4.8-point greater reduction in Young Mania Rating Scale (YMRS) total score versus placebo at Week 3 (effect size −0.69; p<.0001). Statistically significant separation from placebo was observed as early as Day 3 and was sustained through Week 3.
For the key secondary endpoint of overall illness severity, measured by the Clinical Global Impression–Severity (CGI-S) score, patients treated with CAPLYTA showed significantly greater improvement versus placebo at Week 3 (least-squares mean difference, −0.5; P<.0001).
Twice as many patients treated with CAPLYTA achieved clinical response, defined as a ≥50% reduction in YMRS total score, compared with placebo (45.8% vs. 20.9%; p<.0001).
Safety and Tolerability
CAPLYTA was well tolerated, with low rates of discontinuation and a safety profile consistent with its established profile. The most common treatment-related adverse events reported at a rate of at least 5% with CAPLYTA and at least twice the rate of placebo were dry mouth (7.9% vs. 3.4%) and nausea (7.9% vs. 2.3%).
Clinical Context
Bipolar disorder (搜索) is a complex, lifelong condition affecting an estimated 37 million people worldwide, marked by recurring depressive and manic episodes. Mania is a defining feature of bipolar I disorder (搜索), characterized by abnormally elevated or irritable mood and/or increased energy or activity, and most people experience it alongside depressive episodes over the course of the illness. Symptoms can include grandiosity, decreased need for sleep, racing thoughts, distractibility, and risk-taking behavior. Manic episodes can escalate quickly and often require hospitalization for safety and treatment, and the condition is one of the leading causes of disability worldwide. Treatment options remain limited by variability in response and tolerability concerns.
"Mania is among the most dangerous and worrisome phases of bipolar disorder (搜索), and treating it effectively takes more than partial or temporary relief of symptoms; it means bringing the episode itself under control as quickly as possible," said Michael E. Thase, M.D., Professor of Psychiatry and Chief, Division of Mood and Anxiety Disorders Treatment & Research Program, University of Pennsylvania. "These results are encouraging because CAPLYTA not only significantly improved the symptoms of mania, but did so as early as Day 3, with benefits sustained through Week 3, supporting its potential to meaningfully advance how we treat acute mania in bipolar I disorder (搜索)."
Existing Approvals and Development Program
CAPLYTA is an oral, once-daily atypical antipsychotic approved by the U.S. Food and Drug Administration in adults for depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy or as adjunctive therapy with lithium or valproate; for schizophrenia (搜索); and as adjunctive therapy with antidepressants for major depressive disorder (搜索). The FDA approved a supplemental new drug application for relapse prevention in schizophrenia in April 2026.
While the mechanism of action of CAPLYTA is unknown, its efficacy could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors. Lumateperone's pharmacology also includes effects on glutamatergic signaling via GluN2B-containing NMDA receptors (搜索), a profile that differs from standard D2 antagonists such as olanzapine and risperidone and from the D3-preferring partial agonist cariprazine.
The bipolar I mania field includes approved mood stabilizers such as lithium and valproate and multiple atypical antipsychotics including olanzapine, quetiapine, aripiprazole, and cariprazine. Lumateperone's tolerability profile, particularly its low metabolic burden, and the prospect of covering both poles of the illness with a single oral agent may differentiate it if the mania indication is secured.
"Bipolar I disorder (搜索) is a lifelong, cycling illness, and managing it means navigating both manic and depressive episodes over time, each with distinct treatment needs," said Jane Tiller, Vice President, Global Head of Development, Neuroscience, Johnson & Johnson. "These Phase 3 results build on the established efficacy of CAPLYTA in bipolar depression and represent an important step in evaluating its potential to address both depressive and acute manic episodes associated with bipolar I disorder."
A second pivotal Phase 3 study (Study 452) evaluating CAPLYTA for the treatment of manic episodes in adults with bipolar I disorder (搜索) has been completed, and data analysis is underway. Johnson & Johnson said it plans to discuss data from both Study 451 and Study 452 with regulators to determine next steps for a potential mania filing. Johnson & Johnson gained CAPLYTA through its acquisition of Intra-Cellular Therapies.